Solid Biosciences (Solid Biosciences) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Solid Biosciences Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Solid Biosciences's Capital Expenditure for the three months ended in Mar. 2024 was $-0.15 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-26.86 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Solid Biosciences Capex-to-Operating-Income Historical Data

The historical data trend for Solid Biosciences's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solid Biosciences Capex-to-Operating-Income Chart

Solid Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

Solid Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Solid Biosciences's Capex-to-Operating-Income

For the Biotechnology subindustry, Solid Biosciences's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solid Biosciences's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's Capex-to-Operating-Income falls into.

Solid Biosciences Capex-to-Operating-Income Calculation

Solid Biosciences's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-1.515)	/	-104.315
	=	N/A

Solid Biosciences's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.149)	/	-26.862
	=	N/A

Solid Biosciences (NAS:SLDB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Solid Biosciences Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Solid Biosciences's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Solid Biosciences (Solid Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Solid Biosciences Inc (NAS:SLDB) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129

Website

https://www.solidbio.com

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Kevin Tan	officer: CFO & Treasurer	20 HICKORY ROAD, WELLESLEY MA 02482
Ilan Ganot	director, officer: Chief Executive Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
David T Howton	officer: See Remarks	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jennifer Marlowe	officer: CSO, FA & Cardiac	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Paul Herzich	officer: Chief Technology Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Jessie Hanrahan	officer: Chief Regulatory Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Gabriel Brooks	officer: Chief Medical Officer	C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Carl Ashley Morris	officer: Chief Scientific Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Georgia Keresty	director	C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Clare Kahn	director	141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Bcls Sb Investco, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investo (gp), Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116